5 Endocrinology Headlines You Missed in November 2025

While largely a quiet month for endocrinology, November 2025 was not without its important updates. There were no significant approvals from the US Food and Drug Administration, but glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have continued their advances into other condition centers such as nephrology and cardiology. Additionally, Novo Nordisk has had a rollercoaster month, between the failure of semaglutide to significantly reduce Alzheimer’s progression and amycretin’s superior weight loss outcomes in patients with type 2 diabetes (T2D) compared to placebo.